Mutations in the XPD subunit of the DNA repair/transcription factor TFIIH result in distinct clinical entities, including the cancerprone xeroderma pigmentosum (XP) and the multisystem disorder trichothiodystrophy (TTD), which share only cutaneous photosensitivity. Gene-expression profiles of primary dermal fibroblasts revealed overexpression of matrix metalloproteinase 1 (MMP-1), the gene encoding the metalloproteinase that degrades the interstitial collagens of the extracellular matrix (ECM), in TTD patients mutated in XPD compared with their healthy parents. The defect is observed in TTD and not in XP and is specific for fibroblasts, which are the main producers of dermal ECM. MMP-1 transcriptional up-regulation in TTD is caused by an erroneous signaling mediated by retinoic acid receptors on the MMP-1 promoter and leads to hypersecretion of active MMP-1 enzyme and degradation of collagen type I in the ECM of cell/tissue systems and TTD patient skin. In agreement with the well-known role of ECM in eliciting signaling events controlling cell behavior and tissue homeostasis, ECM alterations in TTD were shown to impact on the migration and wound-healing properties of patient dermal fibroblasts. The presence of a specific inhibitor of MMP activity was sufficient to restore normal cell migration, thus providing a potential approach for therapeutic strategies. This study highlights the relevance of ECM anomalies in TTD pathogenesis and in the phenotypic differences between TTD and XP.
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NER-defective disorders | TFIIH | transcription | MMP-1 | collagen degradation T he extracellular matrix (ECM) is a complex structural network that surrounds and supports cells within connective tissues. It generally includes three major types of macromolecules: fibrous proteins (collagens and elastic fibers), glycoproteins (such as fibronectins and laminins), and glycosaminoglycans/ proteoglycans. The type, amount and composition of the ECM give tissues their unique physical and biological properties (1) . Notably, the ECM is not only a structural scaffold but also exhibits important functional roles in controlling key cellular events (e.g., adhesion, migration, proliferation, differentiation, and survival) involved in tissue homeostasis, development, inflammation, and tissue repair (2, 3). Thus, inherited or acquired structural alterations as well as metabolic disturbances of the ECM may cause cellular and tissue changes leading to the onset and progression of specific disorders, such as those affecting the connective tissues (osteogenesis imperfecta, Ehlers-Danlos syndrome, and Marfan's syndrome) or demanding ECM degradation (tumor invasion and metastasis) (4, 5) . Recently, a reduced synthesis of the ECM component collagen type VI (COL6) was shown in confluent fibroblast cultures from patients with trichothiodystrophy [TTD; Online Mendelian Inheritance in Man (OMIM) #601675] (6), an autosomal recessive disorder characterized by symptoms affecting several tissues and organs (7) . The most relevant features of TTD are hair abnormalities, ichthyotic skin, physical and mental retardation, neurodegeneration, and signs of premature aging. Moreover, about 50% of patients show cutaneous photosensitivity that is associated with an altered cellular response to UV light caused by a defect in nucleotide excision repair (NER), the DNA repair pathway that removes a wide spectrum of DNA lesions, including UV-induced damage. The genes responsible for the photosensitive form of TTD encode the XPB, XPD, and p8/TTDA subunits of the general transcription factor IIH (TFIIH). All of the mutations associated with TTD result in reduced cellular levels (8, 9) and impaired functioning of TFIIH in NER and basal transcription (10) (11) (12) . Furthermore, they may interfere with the role of TFIIH in transcription regulation (13) (14) (15) (16) .
The engagement of TFIIH in distinct cellular processes has provided a rationale for explaining the variety of clinical entities resulting from mutations in the XPD and XPB genes, which are also found in patients with the cancer-prone disorder xeroderma pigmentosum (XP). Notably, premalignant skin lesions and cutaneous tumors have never been reported in TTD. It was suggested that pathological features of XP are associated with mutations that mainly affect the DNA repair activity of TFIIH, whereas those typical of TTD also impair transcription (12, (17) (18) (19) .
To assess whether mutated TFIIH in TTD might alter the transcription of ECM-related genes (thus affecting the strength Significance Despite exhibiting different phenotypes, the UV-sensitive syndromes trichothiodystrophy (TTD) and xeroderma pigmentosum (XP) result from the same mutated genes encoding specific subunits of the DNA-repair/transcription factor TFIIH. The widely accepted notion is that XP cancer proneness results from mutations interfering with DNA repair, whereas TTD clinical hallmarks (namely, hair anomalies, physical and mental retardation, and premature aging) are because of transcriptional alterations. The present study identifies a TTD-specific overexpression of matrix metalloproteinase 1, leading to collagen I degradation in patient skin. This finding explains the clinical features distinguishing TTD from XP (i.e. bone alterations, pregnancy abnormalities and likely lack of skin cancer despite the accumulation of unrepaired DNA lesions) and the features that TTD shares with osteogenesis imperfecta caused by COL1 mutations.
and architecture of the ECM and contributing to the wide clinical spectrum of TTD), we compared gene-expression profiles of primary fibroblasts from TTD patients and their parents. In TTD, we found a cell type-specific transcription overexpression of the matrix metalloproteinase 1 (MMP-1), a gene encoding a zinc-containing endopeptidase that plays a key role in physiological and pathological tissue remodeling (20) (21) (22) (23) . The MMP-1 transcription up-regulation results in high secretion of the active MMP-1 enzyme and subsequent degradation of collagen type I (COL1) in cell/tissue cultures, as well as in patient skin. We investigated the molecular mechanisms responsible for this transcription deregulation, which is specific for TTD and not XP mutations. Moreover, we demonstrated that the abundant secretion of active MMP-1 is responsible for altered migration features of TTD cells, a defect that can be recovered by using a specific MMP inhibitor.
Results

MMP-1 Overexpression Is a Specific Trait of TTD/XP-D Dermal Fibroblasts.
A high-throughput gene-expression profiling by RealTime ready Custom Panels was applied to RNA pools obtained by mixing equal amounts of RNA from primary dermal fibroblasts of either 11 TTD patients (TTD pool) or 11 healthy donors (normal pool). Ten TTD parents were included in the normal donor sample to minimize gene-expression variations resulting from different genetic backgrounds. The analyzed TTD patients are representative of different types and combinations of mutated XPD alleles (TTD/XP-D), including the changes arg112his and arg722trp, which represent the most frequent alterations observed in TTD (Table S1 ). The TTD and normal pools were investigated for the expression of 83 genes encoding proteins related to the ECM and involved in cell-to-cell and cell-to-matrix interactions (Table S2) . Using a ±2.5-fold change cut-off value, we identified eight ECM genes deregulated in TTD, three being up-and five down-regulated (Fig. S1) . Intriguingly, five of the deregulated genes encode proteins belonging to the family of MMPs, which are proteolytic enzymes responsible for ECM turnover and degradation. The remaining three genes encode a member of the EGF-containing fibulin-like family of extracellular matrix glycoproteins (EFEMP1), the elastin (ELN) protein, and the structural component laminin β3 (LAMB3), respectively.
The expression of these eight ECM-related genes was further investigated by individually analyzing several fibroblast strains from healthy donors and TTD or XP patients mutated in XPD (Fig. S2 ). MMP-1 is the only gene transcriptionally deregulated in all TTD/XP-D cell strains, irrespective of whether they are homozygotes, hemizygotes, or compound heterozygotes, with a 2-to 14-fold expression increment compared with normal fibroblasts ( Fig. 1A and Fig. S3A ). Strikingly, this finding holds true for TTD cells mutated in either the XPB or TTDA gene as well ( Immunoblot analysis of whole-cell extracts revealed that TTD fibroblasts contain higher amounts of the 52-and 57-kDa MMP-1 proenzyme compared with fibroblasts from normal donors, healthy TTD parents, and XP/XP-D patients (Fig. 1B) . This finding attests that the MMP-1 transcription up-regulation specifically detected in TTD primary dermal fibroblasts results in abnormally high levels of the MMP-1 protein.
To clarify whether the observed MMP-1 overexpression also affects epidermal cells, we analyzed primary keratinocytes actively proliferating in vitro or induced to differentiate by increasing calcium levels, which mimics the naturally occurring calcium gradient found in the human epidermis (24) . We observed that TTD24PV proliferating as well as differentiating keratinocytes contain an MMP-1 transcript and protein levels similar to those observed in the corresponding normal keratinocytes ( Fig. 1 C and D), thus demonstrating that MMP-1 overexpression in TTD is cell-type-specific.
Reduced Retinoid Receptor Binding to MMP-1 Promoter Accounts for MMP-1 Overexpression in TTD Fibroblasts. The phorbol myristate acetate (PMA) stimulates the expression and production of MMP-1 in human fibroblasts through the binding of the c-Jun factor to the AP-1 site of the MMP-1 promoter (25, 26) . Conversely, all-trans-or 9-cis-retinoic acid (RA) isomers reduce MMP-1 expression via the formation of a large repressor complex containing c-Jun that binds directly to the AP-1 site and apparently tethers the retinoid receptors (RARs and RXRs) to the complex (27) . To elucidate the mechanistic basis of MMP-1 transcription up-regulation in TTD, we analyzed the MMP-1 expression in normal and TTD fibroblasts treated with PMA and RA either singly or in combination ( Fig. 2A and Fig. S3B ). In normal fibroblasts, the steadystate level of MMP-1 progressively increases and peaks at 12-h PMA treatment and then slowly decreases. In contrast, the addition of RA to the culture medium does not alter the MMP-1 basal expression but slightly lowers the PMA-induced MMP-1 expression. Also in TTD fibroblasts the MMP-1 expression drastically increases during PMA treatment and is unaffected by RA. Interestingly, the PMA-induced expression of MMP-1 is further increased (rather than slightly reduced) by the presence of RA in the combined treatment. Overall, these findings indicate that in TTD cells the RA-activated signaling pathway erroneously impacts on the transcriptional machinery acting on the MMP-1 promoter. Because it is well known that XPD mutations prevent TFIIHdependent transcriptional transactivation by RAR (13), we investigated the recruitment at MMP-1 promoter of key components of the transcriptional machinery, namely the hypophosporylated RNA polymerase II (RNApol IIA), the TFIIH complex, and the transcription factors c-Jun and RARβ. The analysis was performed by ChIP assays in basal conditions and during the PMAinduced transcription up-regulation of MMP-1. Both in normal and TTD fibroblasts, the highest occupancy of RNApol IIA and TFIIH (visualized by the presence of its XPB subunit) is observed on the transcription start site of the MMP-1 promoter, whereas c-Jun and RARβ are localized mainly on the AP-1 binding site at position −77/−72 (Fig. 2 B and C) . The PMA treatment promotes the recruitment of RNApol IIA, c-Jun, and TFIIH at the MMP-1 promoter (compare the level at 4-and 8-h treatment with that of untreated cells in Fig. 2C) , with a twofold higher efficiency in TTD than in normal fibroblasts, thus paralleling the respective increment of MMP-1 expression. Conversely, the occupancy of RARβ in normal fibroblasts is reduced following transcription activation, according to the previously described repressive role of RARs on MMP-1 transcription (27) . Of relevant note, the basal level of RARβ in TTD fibroblasts is reduced compared with normal as well as XP/XP-D fibroblasts (Fig. S3C) .
Overall, these results demonstrate that the increased expression of MMP-1 in TTD fibroblasts is associated with an enhanced recruitment of c-Jun and a reduced occupancy of the RARβ repressor complex on the AP-1 binding site of the MMP-1 promoter.
MMP-1 Overexpression Leads to COL1 Degradation in the ECM of TTD
Fibroblasts. The MMP-1 proenzyme is secreted by the cells in its latent form and requires extracellular activation by proteolytic cleavage (21) . Thus, we searched for the presence of the proteolytically cleaved forms of MMP-1 (46-42 kDa) in the extracellular environment of TTD and normal fibroblasts. Immunoprecipitation experiments with anti-MMP-1 antibodies revealed a progressive accumulation of the proenzyme as well as the 46-and 42-kDa isoforms in culture media conditioned by TTD fibroblasts (Fig. 3A, Left) . These proteins are not observed in the culture media of normal fibroblasts even at 72 h, when they are clearly detectable in TTD culture media (Fig. 3A, Right) . Compared with normal, TTD fibroblasts secrete twice the amount of MMP-1 protein, as evaluated by using the MMP-1 Human Biotrak ELISA System that directly measures the amount of soluble MMP-1 (Fig. 3B) . We then investigated whether the secreted forms of MMP-1 are active and capable of triggering the cleavage of interstitial collagen triple helix, mainly the fibrillar COL1. In culture media conditioned by TTD fibroblasts but not normal fibroblasts, zymogram analysis revealed the presence of enzymatic activities with the molecular weights of the active recombinant MMP-1 isoforms that are also capable of degrading COL1 (Fig. 3C) . Accordingly, a strong reduction of the α1 subunit of COL1 (COL1A1) was detected uniquely in TTD cells (Fig.  3D ) despite the nearly normal COL1A1 expression (Table S2) . Conversely, the levels of collagen types V (COL5) and VII (COL7), which are not MMP-1 substrates, are within the range detected in normal and XP/XP-D cells (Fig. 3D) .
The effect of MMP-1 overexpression on COL1 distribution was evaluated in more sophisticated in vitro systems, such as tridimensional (3D) tissue-like matrices stained with Masson trichrome goldner to disclose collagen fibers. Collagen is undetectable in the area around 53-60% of TTD fibroblasts versus 9-19% of normal fibroblasts in 4-wk-old 3D COL1 lattices (representative results in Fig. 4A ). This analysis was extended to whole reconstructed skin equivalents in which TTD or normal primary keratinocytes were grown on 3D COL1 lattices containing either normal or TTD fibroblasts. The presence of TTD fibroblasts is associated with areas devoid of collagen, independently of the cocultivated keratinocytes (Fig. 4B) . Taken together, these results demonstrate that TTD dermal fibroblasts secrete high levels of active MMP-1, which are responsible for COL1 impoverishment in the ECM of monolayer or 3D fibroblast cultures as well as TTD skin equivalents.
TTD Fibroblasts Show Altered Wound-Healing Response That Is
Recovered by Inhibiting MMP Activity. To clarify whether the high secretion of active MMP-1 and subsequent degradation of COL1 in the ECM might alter the migratory features of TTD fibroblasts, we compared the wound closure in monolayers of several TTD fibroblasts with that of normal and XP fibroblasts by wound-healing assays. In the time-frame of 36 h, TTD fibroblasts are able to close the wound, whereas normal and XP cells do not (Fig. S4A) . Over this period, all TTD fibroblasts show a higher migration rate compared with normal and XP cells (Fig. S4B) . We then analyzed the effect of normal and TTD cells on the wound-healing response of XP17PV fibroblasts up to 36 h after wound generation (Fig. 5, Top) . In this setting, TTD but not normal fibroblasts are able to speed up the migration rate of XP17PV cells, demonstrating that TTD cells secrete molecules capable of influencing cell migration. Next, we performed woundhealing assays in the presence of galardin (GAL), a synthetic inhibitor of MMPs (28, 29) . The addition of GAL to the culture medium is sufficient to reduce the migration speed of TTD23PV fibroblasts, whereas it has no effect on the migration of XP cells (Fig. 5, Middle) . Moreover, GAL is also able to slow down the migration of XP17PV fibroblasts surrounded by TTD23PV cells (Fig. 5, Bottom) , thus demonstrating that the metalloprotease activity secreted by TTD fibroblasts influences XP cell migration. By showing a causal relationship between migration ability and MMP activity, these findings demonstrate that the MMP-dependent degradation of the ECM is the main event responsible for the high migration rate of TTD cells.
Reduced Levels of COL1 Characterize TTD Skin Tissue. Finally, to clarify whether MMP-1 transcription deregulation in TTD also affects the ECM in vivo, we analyzed the presence and distribution of COL1A1 in the skin of the 18-y-old patient TTD8PV showing a moderately affected phenotype. Because premature aging is a relevant feature of TTD (7, 30) , the patient skin was compared with that of four normal donors of different ages, namely a 19-, 21-, 29-, and 58-y-old (Fig. 6) . In parallel, we analyzed the distribution of COL5, which is not a substrate of MMP-1. Immunohistochemistry staining with anti-COL1A1 antibody on formalin-fixed paraffin-embedded skin sections clearly show the presence of COL1A1 in the dermis of normal donors and its reduction in aged skin as a consequence of MMPdependent dermal collagen fragmentation (31) . In TTD skin, despite a normal distribution and a strong signal of COL5A1, a very weak COL1A1 staining is found.
Overall, these results demonstrate that MMP-1 overexpression in TTD dermal fibroblasts leads to high secretion levels of active MMP-1 that, in turn, degrades interstitial collagen and affects the ECM not only in cell-culture systems but also in patient skin.
Discussion
The ECM is a dynamic structure that interacts with cells and generates signals controlling cell behavior and tissue homeostasis. The diversity and functional importance of the ECM is illustrated by the occurrence of numerous genetic and acquired connective tissue disorders in which bone, cartilage, skin, muscle, brain, eye, and cardiovascular systems are differentially affected (5) . In the present study, we demonstrate that TTD-specific mutations affecting the general TFIIH are responsible for the overexpression of MMP-1 gene in primary dermal fibroblasts and, in turn, for the loss of the interstitial component COL1 in the patient skin dermis. The dissection of the underlying mechanistic defect led to the identification of a reduced occupancy of the RARs on the AP-1 binding site of the MMP-1 promoter (Fig. 2C and Fig.  S3C ). The RAR interaction with the c-Jun component of the AP-1 complex was previously demonstrated to repress MMP-1 transcription (27) . Thus, the reduced amount of the RAR repressor on the MMP-1 promoter offers a clue to explain the MMP-1 overexpression in TTD cells that are otherwise characterized by a malfunctioning basal transcription factor. It was previously shown that TFIIH phosphorylates specific nuclear hormone receptors, including RARs, via its cdk7 kinase subunit, thus leading to transcriptional transactivation of hormone-responsive genes (13) . This raises the possibility that TTD mutations, which are known to impair the stability of the TFIIH complex, might differentially affect the transcriptional activity of RARs and their binding affinities for other transcription factors, cofactors, and chromatin remodelers. Interestingly, the MMP-1 transcription deregulation occurs specifically in TTD dermal fibroblasts and not in keratinocytes, which have different embryonic origins (mesodermal and ectodermal, respectively). This finding suggests the involvement of additional cell/tissue-specific transcription factors likely interacting with RARs, which may contribute to the increased levels of MMP-1 mRNA in TTD fibroblasts. Furthermore, the lack of correlation among MMP-1 overexpression, reduced level of TFIIH, and mutation sites, which are known to differentially affect RAR phosphorylation (13) , suggests that other TFIIH-dependent signaling events must contribute to the reduced levels of RARs on the MMP-1 promoter.
MMP-1 transcriptional deregulation results in the increased secretion of active MMP-1 isoforms and consequent degradation of COL1 (Fig. 3 C and D) , the major structural component of interstitial ECM that provides mechanical strength to the skin. The in vivo relevance of this event was demonstrated by showing that COL1 degradation occurs not only in monolayer and 3D fibroblast cultures (Fig. 4A ) but also in skin equivalent, a system mimicking the in vivo cell environment (Fig. 4B) . Even more remarkably, COL1-depletion was observed in TTD patient skin as well (Fig. 6) . Because the correct balance between deposition and degradation of ECM collagens is altered in TTD, the outcome is a high migration rate of TTD fibroblasts, as demonstrated by wound-healing assays (Fig. S4) . During the process of in vivo wound healing, normal dermal fibroblasts, which are the primary collagen-producing cells in the dermis, contribute to the repair by filling the wound with abundant provisional ECM, a key component of the granulation tissue. The persistent overexpression of MMP-1 in TTD dermal fibroblasts would result in excessive COL1 proteolysis within granulation tissue and likely in the scar tissue, thus protracting the period of healing. Indeed, a prolonged time of wound repair in TTD patients is anecdotally reported by several parents. Remarkably, we showed that the altered migration features of TTD cells are recovered by inhibiting the metalloprotease activity (Fig.  5) , suggesting a new potential target for therapeutic approaches.
Besides a key structural role in skin, COL1 is the main proteinbuilding block in bone, and is important in other connective tissues, such as tendons and ligaments. Accordingly, reduced amounts of normal COL1 because of a mutated COL1A1 or COL1A2 allele, are typically found in the mildest form of osteogenesis imperfecta (OI type I), which is characterized by fragile bones and reduced bone density often associated with slight spinal curvature, loose joints, muscle weakness, lax ligaments, easy bruising, blue sclerae, and early loss of hearing (32) . Notably, skeletal abnormalities, including kyphosis, osteopenia and osteosclerosis, abnormalities in joints, muscle tone and deep tendon reflex, and sensorineural hearing loss are reported in several TTD patients just as are bone fragility, kyphosis and reduced mineral density of vertebrae in the TTD mouse model (30, 33, 34) .
ECM alterations might also explain other TTD-related features. Recent molecular epidemiological studies on pregnancy and neonatal abnormalities in the mothers of patients with XPD mutations showed that 94% of TTD pregnancies (16 of 17) have preterm delivery, pre-eclampsia, hemolysis, elevated liver enzymes and low platelets syndrome, prematurity, and low birth weight. In contrast, none of 17 XP pregnancies had these complications (35, 36) . It is worthwhile considering that the human placenta, whose function is to facilitate nutrient exchanges between the fetus and the mother, contains abundant ECM components and well-preserved endogenous growth factors. Because the placenta consists of both fetal and maternal tissue, we are tempted to speculate that the pregnancy complications in the mothers of TTD patients could be partially ascribed to the fetal ECM alterations affecting the structure and functionality of the placenta. This observation is supported by the finding that gestational abnormalities were found only when the pregnancy resulted in TTD-affected individuals and not in their unaffected siblings (37) . Overall, our previous and present studies suggest how the ECM alterations might contribute to TTD etiopathogenesis.
It is yet to be ascertained whether ECM alterations may also contribute to other features that distinguish TTD from the XP phenotype, such as cancer proneness. It is well known that ECM remodeling plays a role in cancer initiation, progression, and invasion (3, 38) . Excess ECM production or reduced ECM turnover are prominent in cancer development and various collagens, including collagen type I, II, III, V, and IX, show increased deposition during tumor formation. Increased MMP1 levels were shown in dermal fibroblasts, dermal equivalents, and skin sections from XP patients mutated in the XPC gene, leading to the suggestion that MMP-1 overespression could be a worsening actor toward exacerbated premature skin aging and tumor susceptibility in these patients. Nevertheless, no evidence of ECM alterations was reported in the analyzed XP-C cells and tissues (39) . Further studies are needed to ascertain whether the reduced levels of COL1 observed in the present study together with the previously reported lowered amount of COL6A1 secreted by TTD dermal fibroblasts (6) might create a microenvironment not conducive for cancer cells to survive and grow.
Materials and Methods
Patient fibroblast strains used in this study are listed in Table S1 . Normal primary fibroblasts were from 4 genetically unrelated healthy donors (C3PV, C5BO, C377RM, and B119) and 10 phenotypically normal TTD parents (mother and father of the patients TTD7PV, TTD8PV, TTD11PV, TTD2PV/TTD3PV, and TTD12PV/TTD15PV). Experiments on keratinocytes were performed on the normal cell strains K490 and K1690 and the only available TTD keratinocyte strain (TTD24PV). Fibroblast-populated collagen lattices and reconstructed epidermis were prepared as detailed in SI Materials and Methods. Gene-expression analysis was performed by RealTime ready Custom Panels (Roche) and quantitative realtime RT-PCR. Primer sequences are listed in Table S3 . Immunoprecipitation, immunohistochemistry, and immunoblot experiments were performed according to standard protocols. ChIP assays were previously described (6) . Zymogram analysis were obtained in nonreducing conditions on 10% (wt/vol) SDS/PAGE gels embedded with 0.8 mg/mL rat tail type I collagen (Sigma). Wound-healing assays were performed using a culture-insert (Ibidi) according to the manufacturer's instructions. Full details are provided in SI Materials and Methods.
